Effect of mibefradil, a T-type calcium-channel blocker in pigs with heart failure: comparison with amlodipine, an L-type calcium-channel blocker

2004 ◽  
Vol 10 (5) ◽  
pp. S187
Author(s):  
Ishikawa Kimito ◽  
Ohtsuka Sadanori ◽  
Yamaguchi Iwao
Keyword(s):  
Heart Failure ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Channel Blocker

scholarly journals Additive Beneficial Effects of the Combination of a Calcium Channel Blocker and an Angiotensin Blocker on a Hypertensive Rat-Heart Failure Model

2004 ◽  
Vol 27 (10) ◽  
pp. 771-779 ◽  
Author(s):  
Shokei KIM-MITSUYAMA ◽  
Yasukatsu IZUMI ◽  
Yasuhiro IZUMIYA ◽  
Kaoru YOSHIDA ◽  
Minoru YOSHIYAMA ◽  
...  
Keyword(s):  
Heart Failure ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Rat Heart ◽  
Channel Blocker ◽  
Failure Model ◽  
Beneficial Effects ◽  
Hypertensive Rat ◽  
Heart Failure Model

scholarly journals Effect of Mibefradil, a T-Type Calcium Channel Blocker, on Morbidity and Mortality in Moderate to Severe Congestive Heart Failure

Circulation ◽  
2000 ◽  
Vol 101 (7) ◽  
pp. 758-764 ◽  
Author(s):  
T. Barry Levine ◽  
Peter J. L. M. Bernink ◽  
Abraham Caspi ◽  
Uri Elkayam ◽  
Edward M. Geltman ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Channel Blocker ◽  
Severe Congestive Heart Failure ◽  
Morbidity And Mortality

Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension

2018 ◽  
Vol 23 (5) ◽  
pp. 433-445 ◽  
Author(s):  
Sandip Chaugai ◽  
Lhamo Yangchen Sherpa ◽  
Amir Ali Sepehry ◽  
Scott Reza Jafarian Kerman ◽  
Hisatomi Arima
Keyword(s):  
Heart Failure ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Calcium Channel Blockers ◽  
Lower Risk ◽  
Randomized Clinical Trials ◽  
Channel Blocker ◽  
Channel Blockers ◽  
Dihydropyridine Calcium Channel Blocker ◽  
Long Acting

Background: Dihydropyridine calcium channel blockers are a heterogeneous group of antihypertensive drugs. Long-acting dihydropyridine agent amlodipine is widely used for monotherapy and combination therapy for hypertension in clinical practice, while intermediate-acting dihydropyridine agents have shown inconsistent results in randomized clinical trials (RCTs). Methods and Results: A meta-analysis of 18 RCTs enrolling a total of 80,483 patients with hypertension followed for a mean of 51.4 months was performed. Amlodipine therapy was associated with 25% higher risk of heart failure (relative risk [RR]: 1.25, 95% confidence interval [CI], 1.05-1.49, P = .019) but 17% lower risk of stroke (RR: 0.83, [95% CI, 0.72-0.97], P = .009) without statistically significant effect on acute myocardial infarction (AMI) compared to major alternative antihypertensive therapy (MAAT), including β-blocker, diuretic, angiotensin-converting enzyme inhibitor, or angiotensin-receptor blocker. Intermediate-acting dihydropyridine calcium channel blocker therapy was associated with 25% higher risk of heart failure (RR: 1.25, [95% CI, 1.06-1.47], 0.005, P = .005) and 26% higher risk of AMI (RR: 1.26, [95% CI, 1.05-1.51], 0.019, P = .019) compared to MAAT. Results of the subgroup analysis suggested that the intermediate-acting dihydropyridine calcium channel blocker was associated with higher risk of heart failure (RR: 1.30, [95% CI, 1.08-1.56], P = .005) and AMI (RR: 1.50, [95% CI, 1.01-2.22], P = .043) compared to renin–angiotensin system blockers and a trend toward higher risk of AMI (RR: 1.17, [95% CI, 0.99-1.38], P = .064) compared to conventional therapy, including β-blockers and diuretics. Meta-regression analyses suggested that long-acting dihydropyridine calcium channel blocker is associated with lower risk of AMI ( B: −0.327, [95% CI, −0.530 to −0.123], P = .002) with a trend toward lower risk of stroke ( B: −0.203, [95% CI, −0.410 to 0.003] P = .054). Conclusions: This study suggests that Amlodipine offers greater protection against major complications of hypertension compared to intermediate-acting dihydropyridine calcium channel blockers.

Acute Hemodynamic Effects of Nilvadipine, a New Calcium Channel Blocker, in Patients with Congestive Heart Failure

1990 ◽  
Vol 15 (2) ◽  
pp. 317-322 ◽  
Author(s):  
Hiroshi Sato ◽  
Hiroshi Ikenouchi ◽  
Teruhiko Aoyagi ◽  
Hiroshi Matsui ◽  
Takatoshi Mochizuki ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Channel Blocker ◽  
Hemodynamic Effects
Sign in / Sign up

Export Citation Format

Share Document